In the current study, we analyzed the effects of low-dose IL-2 combined with TCZ on clinical symptoms, immune-related indicators, and CD4+T lymphocyte subsets in RA patients, and evaluated its safety. Here, CD4 is linked to rheumatoid arthritis.